Skip to search formSkip to main contentSkip to account menu

SM 108

Known as: SM-108 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

4-carbamoylimidazolium 5-olate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
Induction of erythroid differentiation of K562 cells by 4-carbamoylimidazolium 5-olate (SM-108).
1989
1989
[Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
A total of 165 patients were entered into this study and 140 were evaluate for effects and 165 for toxicities. Of 39 patients… 
1989
1989
[Phase I study and early phase II of SM-108 (4-carbamoylimidazolium-5-olate) in lung cancer. SM-108 Study Group].
Phase I study with a new oral purine antagonist, SM-108, was conducted in a total of 73 cases in a 5-day consecutive schedule… 
1988
1988
[Treatment of myelodysplastic syndrome using SM-108 in relation to stem cell kinetics].
Eighteen patients in a high-blast group of myelodysplastic syndrome were treated with low-dose SM-108 (4-carbamoylimidazolium 5… 
1988
1988
177 TWO DISTINCT TARGET SITES ON IMP DEHYDROGENASE IN CHEMOTHERAPY
The inhibitory mechanisms of ribavirin 5′-monophosphate, (RMP), SM-108 nucleotide (bredinin 5′-monophosphate, BMP) and thiazole-4… 
1987
1987
[Clinical trial of SM-108 in myeloproliferative disorders].
SM-108 (4-carbamoylimidazolium-5-olate) is a new purine antagonist which blocks IMP dehydrogenase, the key enzyme of de novo GMP… 
1986
1986
Selective reduction of intracellular guanosine 5'-triphosphate pool by 4-carbamoylimidazolium 5-olate in murine tumor cells.
Ehrlich carcinoma and P388 leukemia cells were rendered resistant to 4-carbamoylimidazolium 5-olate (SM-108), and assessments… 
1983
1983
Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors.
By designing optimal administration schedules, it was found that 4-carbamoylimidazolium 5-olate (SM-108) showed an excellent… 
1982
1982
New antitumor imidazole derivative, 5-carbamoyl-1H-imidazol-4-yl piperonylate, as an inhibitor of purine synthesis and its activation by adenine phosphoribosyltransferase.
The mechanism of action of 5-carbamoyl-1H-imidazol-4-yl piperonylate (SL-1250), which has a broad antitumor spectrum, was… 
1982
1982
Collateral sensitivity of 6-mercaptopurine-resistant sublines of P388 and L1210 leukemia to the new purine antagonists, 5-carbamoyl-1H-imidazol-4-yl piperonylate and 4-carbamoylimidazolium 5-olate.
Two new purine antagonists, 5-carbamoyl-1H-imidazol-4-yl piperonylate (SL-1250) and 4-carbamoylimidazolium 5-olate (SM-108), were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)